Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1944-446X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer ; volume:34 ; number:1 ; day:16 ; month:6 ; year:2015 ; pages:41-49 ; date:1.2015
Chinese journal of cancer ; 34, Heft 1 (16.6.2015), 41-49, 1.2015
- Urheber
-
López-Guerrero, José Antonio
Romero, Ignacio
Poveda, Andrés
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.5732/cjc.014.10278
- URN
-
urn:nbn:de:101:1-2021081720170996311172
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- López-Guerrero, José Antonio
- Romero, Ignacio
- Poveda, Andrés
- SpringerLink (Online service)
Ähnliche Objekte (12)
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer